All In Biotech

Drug Trial Radar · NCT06682611

Safety and Efficacy of SYHA1813 Single Agent or in Combination With Different Regimens in Unresectable Locally Advanced or Metastatic Solid Tumors.

An, Phase Ib/II Clinical Trial to Evaluate the Safety and Efficacy of SYHA1813 Single Agent or in Combination With Different Regimens in Unresectable Locally Advanced or Metastatic Solid Tumors.

Last checked: Nov 19, 2026Latest source record: Nov 12, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingRandomized with 380 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

380

Planned (sponsor's estimate)

Start

Nov 13, 2024

Primary completion

Nov 13, 2026

Study completion Nov 13, 2027

Sponsor

Sponsor type
Industry
First posted
Nov 12, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is an open-label, multi-center, multi-cohort, phase Ib/II clinical trial, divided into 8 cohorts according to tumor types. Cohorts 1-4 are SYHA1813 combined with different regimens, including safety run-in stage and cohort expansion stage. Cohorts 5-8 are SYHA1813 monotherapy and only include the expansion cohorts. The primary objective was to evaluate the safety and efficacy of SYHA1813 single agent or in combination with different regimens in unresectable locally advanced or metastatic solid tumors.

Conditions

  • Unresectable Locally Advanced or Metastatic Solid Tumors

Interventions

  • SYHA1813Drug

    In accordance with the protocol

  • SG001Drug

    In accordance with the protocol

  • HB1801Drug

    In accordance with the protocol

  • CarboplatinDrug

    In accordance with the protocol

  • CisplatinDrug

    In accordance with the protocol

  • PaclitaxelDrug

    In accordance with the protocol

  • EtoposideDrug

    In accordance with the protocol

  • EverolimusDrug

    In accordance with the protocol

  • RegorafenibDrug

    In accordance with the protocol

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. DLTTime frame: Up to approximately 2years
  2. Frequency and severity of TEAE and SAETime frame: Up to approximately 2years
  3. ORRTime frame: Up to approximately 2 years
  4. PFSTime frame: Up to approximately 2years

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.